Data from a phase II trial designed to investigate the efficacy of the pan αv-integrin inhibitor abituzumab in patients with metastatic CRPC (mCRPC) reveal that abituzumab, compared with luteinizing hormone receptor agonists/antagonists has no effect on progression-free survival (PFS). However, patients receiving abituzumab had a significant reduction in the progression of bone metastasis after a follow-up duration of 24 months. This effect merits further investigation.